Trace Neuroscience has launched in the U.S. with over $100 million in financing and a goal to develop its UNC13A-targeted treatment for ALS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback